ABSTRACT During normal pregnancy, the levels of placental GH in the maternal circulation increase significantly until 35 wk of gestation. We have previously shown that these levels are

significantly reduced in cases of intrauterine growth retardation (IUGR). To better understand the basis of this observation, we have studied the expression of placental GH in placentas from

normal births (_n_ = 6) and births with IUGR (_n_ = 5)._In situ_ hybridization histochemistry was used to determine the mean number of cells per area expressing this message, as well as the

mean level of specific mRNA per cell. We have found that the mean mRNA signal level per cell of placental GH did not differ between normal or IUGR placentas. However, the mean number of

changes in the placental tissue which result in a reduced number of cells per area that are capable of producing this peptide. SIMILAR CONTENT BEING VIEWED BY OTHERS GALECTIN-3 DEFICIENCY IN

PREGNANCY INCREASES THE RISK OF FETAL GROWTH RESTRICTION (FGR) VIA PLACENTAL INSUFFICIENCY Article Open access 23 July 2020 TRACKING PLACENTAL DEVELOPMENT IN HEALTH AND DISEASE Article 29

June 2020 PLACENTAL IGFBP1 LEVELS DURING EARLY PREGNANCY AND THE RISK OF INSULIN RESISTANCE AND GESTATIONAL DIABETES Article Open access 16 April 2024 MAIN IUGR is of major clinical concern

because there is a close relationship between the degree of growth retardation and perinatal morbidity and mortality. Unfortunately, the mechanisms underlying abnormal fetal growth are not

well understood. It has recently been shown that levels of placental GH in the maternal circulation are significantly reduced in cases of IUGR(1) and that maternal IGF-1 levels positively

correlate with placental GH levels(1, 2). Hence, it is conceivable that placental GH plays a role in the process of IUGR. Placental GH is encoded by the GH-V gene, which belongs to a gene

cluster located on chromosome 17q22-24. This gene cluster consists of 5 loci, beginning 5′ with hGH-N (pituitary GH), and continuing 3′ with hCS-L, hCS-A, hGH-V (placental GH), and hCS-B.

These genes have all been cloned and sequenced and have been shown to contain a high degree of sequence and structural homology(3–5). Placental GH is produced and secreted by the

syncytiotrophoblast(6) and during pregnancy progressively replaces pituitary GH in maternal serum(7–10). On the other hand, it is not detectable in the fetus, nor in the cord blood of the

newborn. A physiologic role for placental GH is suggested by the fact that it binds to human placental tissues(11). Interestingly, placental GH secretion is inhibited by glucose(12),

strongly suggesting a metabolic role of this hormone during gestation. Through its somatogenic activity, placental GH might help to maintain high levels of nutrients in the mother to be

transferred to the fetoplacental unit. Hence, an indirect role in fetal growth is implied. In support of this concept, we have previously shown that placental GH is significantly lower in

maternal serum in cases of IUGR(1). To determine whether the source of the decreased in maternal levels of placental GH during IUGR are due to the reduced ability of the placental tissue to

produce this peptide, semiquantitative _in situ_ hybridization histochemistry was performed. The number of cells per unit area of tissue producing this peptide, as well as the mRNA levels

per cell were determined. METHODS _TISSUE COLLECTION AND PREPARATION_. Placentas from six healthy women with uncomplicated singleton pregnancies, with term delivery (39-41 wk of amenorrhea)

and appropriate weight for gestational age infants were used as controls. IUGR was defined as birth weight below the third percentile on Leroy's chart for term (34-41 wk of

amenorrhea)(13). The mother's clinical and obstetrical histories and the neonate's clinical characteristics were recorded by obstetricians and pediatricians, respectively. The

placentas were macroscopically examined according to Benirschke and Kaufmann(14), and three samples for histologic examination were included in paraffin and stained with hematoxylin-eosin.

The placental weights were correlated to the birth weights. Maternal hypertension was noted in two cases of IUGR. Placental vascular lesions were observed in all cases of IUGR. For _in situ_

hybridization, samples were obtained at the time of birth and taken from areas of the placenta were there was no obvious tissue damage. They were rinsed, immediately frozen on dry ice and

stored at-80°C. Cryostat sections were cut at 20 μm and thaw-mounted onto poly-L-lysine (50 μg/mL)-coated slides. Tissue slices were stored at-80°C until hybridization histochemistry was

performed. _LABELING OF OLIGONUCLEOTIDE PROBES_. The probe (Eurogentech, Liège, Belgium) used in these assays was an oligonucleotide probe 30 bases in length and specific for GH-V. It was

end-labeled with 35S-dATP by using terminal transferase (TdT; Boehringer Mannheim) and applied to the tissue at a saturating concentration. _IN SITU HYBRIDIZATION_. Tissue sections were

fixed in 4% paraformaldehyde, treated with 0.25% acetic anhydride in 0.1 M triethanolamine(pH = 8.0), rinsed in 2 × SSC (300 mM NaCl and 30 mM sodium citrate), dehydrated, and delipidated.

The probe was diluted in hybridization buffer and approximately 8 × 105 cpm/slide applied. The slides were then covered with Parafilm, sealed with rubber cement, and incubated overnight in

moist chambers at 37°C. The following day, the parafilm coverslips were removed, and the slides washed in 1 × SSC at room temperature for 15 min(twice), 1 × SSC at 48°C for 30 min (twice),

and 1 × SSC at room temperature for 30 min (twice). They were then dehydrated and dipped in photographic emulsion (Kodak NBT-2 diluted 1:1 with 600 mM ammonium acetate and heated to 45°C).

The slides were then air-dried at room temperature for 15 min, dried in a damp chamber for 1 h, placed in lighttight boxes with dessicant, and exposed at 4°C for 21 d. They were then

developed and counterstained with cresyl violet. _IMAGE ANALYSIS_. Slides were assigned a random three-letter code and analyzed so that the operator was unaware of the experimental group.

Twelve tissue sections per placenta were analyzed. To determine the number of GH-V-positive cells, random fields were analyzed (10 fields/tissue section; hence, 120 fields/placenta), and the

cells were identified under bright-field illumination (50 × magnification). The number of cresyl violet-stained nuclei associated with a cluster of silver grains was determined in each

field. The number of silver grains associated with each nuclei was determined by using an automated image analysis system. This system has previously been described in detail(15). Briefly,

the system consisted of a PixelGrabber video acquisition board (Perceptics Corp., Knoxville, TN) attached to a Macintosh IIci computer. Video images were obtained by a Sony camera attached

to a Zeiss Axioplan Photomicroscope. An average of 20 positive cells (or nuclei)/section was analyzed (240 readings/placenta). Hence, the“number of positive cells” reflects the number of

nuclei in the syncytium associated with a cluster of silver grains. The image analysis readings are reported as mean “grains/cell” and reflect the mean level of specific mRNA signal

associated with individual nuclei. _CONTROL EXPERIMENTS_. Control experiments for the GH-V probe have previously been reported(6). In addition, a 30-base oligonucleotide probe, whose

sequence is not complementary to any known mRNA, was labeled to approximately the same specific activity as the GH-V probe and ran in parallel with all experiments. No specific labeling was

seen with this probe. Experiments were also run to determine the saturating concentration of probe. This probe saturated at a concentration of approximately 1.5 fmol/μL(see Fig. 1). All

experiments were run at a concentration of 1.75 fmol/μL. _STATISTICAL ANALYSIS_. The mean level of grains/cell was determined from the analysis of 240 positive cells/placenta. Approximately

120 fields of view were analyzed to determined the mean number of positive cells/area. A _t_ test was used to determine whether there were significant differences between the two groups. The

significance level was chosen as _p_ < 0.05. RESULTS Figure 1 shows the saturation curve of the oligonucliotide probe used in these experiments. Specific binding saturated at a

concentration of approximately 1.5 fmol/μL, whereas, as expected, the nonspecific binding did not saturate with increasing concentrations of probe. Figure 2 is a darkfield photomicrograph

where a positive signal for GH-V mRNA can be seen. The white clusters of silver grains are each specifically associated with a cresyl violet-stained nucleus. As can be seen in Figure 3A,

there was no difference between normal and IUGR placentas in the mean levels of GH-V mRNA/cell. However, the mean number of GH-V-positive cells/area was significantly greater in normal

placentas when compared with IUGR placentas (Fig. 3B). DISCUSSION It has been established previously that the concentration of placental GH in the maternal circulation is reduced in IUGR(1).

Here we present data suggesting that this observation may not be due only to the decreased size of the IUGR placenta, but also to the reduced ability of this tissue to produce placental GH.

We show that the number of cells per unit area expressing this peptide is decreased in IUGR placentas compared with normal. Interestingly, the synthetic capacity of the individual nuclei,

as expressed in relative levels of placental GH mRNA, does not appear to be modified. As previously reported, placental GH was found to be expressed within the syncytiotrophoblast(6, 16).

Also in accordance with previous studies(6), placental GH-expressing cells tend to be relatively dispersed, but heavily labeled. The fact that in IUGR placentas the relative levels of GH-V

mRNA/cell did not differ from that seen in normal placentas suggests that the synthetic capacity for this peptide, at least at the transcriptional level, of individual nuclei is not altered.

This may indicate that these cells are functioning normally and are receiving the necessary signals to produce this peptide. However, the reduction in the number of cells expressing this

peptide suggests a possible fault in the development or differentiation of the placental tissue. Although the precise role of placental GH during pregnancy remains to be elucidated, it is

not thought to directly influence fetal growth, because it is not detected in the fetal circulation(17). However, both endocrine and paracrine/autocrine functions have been suggested,

including modulation of maternal metabolism and regulation of placental development. Maternal IGF-I levels show a positive correlation with placental GH concentrations(1, 2). Although

maternal IGF-I is synthesized mainly by the liver(18), some placental IGF-I is secreted into the maternal circulation(19). Placental GH, whose secretion is inhibited by glucose(12), might

modulate maternal IGF-I levels by acting on its synthesis in the maternal liver or in the placenta. Indeed, the syncytiotrophoblast is a rich source of IGF-I(20) and also expresses GH

receptors(11). Due to the presence of an autocrine regulation of placental GH within the syncytiotrophoblasts, it has also been suggested that placental GH plays a role in placental

development. Because a relationship between placental size and fetal growth has been clearly established(21), it is therefore possible that placental GH has an indirect effect on fetal

growth. However, whether a reduction in placental GH is the cause of some IUGR or only the result of other underlying causes remains to be elucidated. In this study we show that the low

levels of placental GH in the maternal circulation as a result of IUGR may not be due only to the reduced size of the placenta, but also to the decreased capacity of the existing placental

tissue to produce this peptide. This decline in synthetic capacity may be due to a dysfunction in the development of the placenta as there is a decreased number of placental GH producing

cells. In contrast, the individual capacity of these cells to produce GH does not appear to be affected in IUGR. ABBREVIATIONS * IUGR: intrauterine growth retardation * GH-V: growth hormone

variant REFERENCES * Mirlesse V, Frankenne F, Alsat E, Poncelet M, Evain-Brion D 1993 Placental growth hormone levels in normal and pregnancies with intrauterine growth retardation. _Pediatr

Res_ 34: 439–442. Article  CAS  Google Scholar  * Caufriez A, Frankenne F, Englert Y, Golstein J, Cantraine F, Hennen G, Copinschi G 1990 Placental growth hormone as a potential regulator

of maternal IGF-1 during pregnancy. _Am J Physiol_ 258:E1014–E1019. CAS  PubMed  Google Scholar  * Chen EY, Liao YC, Smith DH, Barrere-Saldaña HA, Gelinas RE, Seeburg PH 1989 The growth

hormone locus: nucleotide sequence, biology and evolution. _Genomics_ 4: 479–497. Article  CAS  Google Scholar  * Hirt H, Kimelman J, Binbaum MJ, Chen EY, Seeburg PH, Eberhardt NL, Barta A

1987 The human growth hormone gene locus: structure, evolution and allelic variations. _DNA_ 6: 59–70. Article  CAS  Google Scholar  * Seeburg PH 1982 The human growth hormone gene

family:nucleotide sequences show recent divergence and predict a new polypeptide hormone. _DNA_ 1: 239–249. Article  CAS  Google Scholar  * Scippo ML, Frankenne F, Hooghe-Peters EL, Igout A,

Velkeniers B, Hennen G 1993 Syncytiotrophoblastic localization of the human growth hormone variant mRNA in the placenta. _Mol Cell Endocrinol_ 92:R7–R13. Article  CAS  Google Scholar  *

Hennen G, Frankenne F, Closset J, Gómez F, Pirens G, El Khayat N 1985 A chorionic GH-like antigen: increasing levels during second half of pregnancy with pituitary GH suppression as revealed

by monoclonal antibody radioimmunoassays. _Int J Fertil_ 30: 27–33. CAS  PubMed  Google Scholar  * Frankenne F, Closset J, Gomez F, Scippo ML, Smal J, Hennen G 1988 The physiology of growth

hormones (GHs) in pregnant women and partial characterization of the placental GH variant. _J Clin Endocrinol Metab_ 66: 1171–1180. Article  CAS  Google Scholar  * Frankenne F, Scippo ML,

Van Beeumen J, Igout A, Hennen G 1990 Identification of placental growth hormone as the growth hormone-V gene expression product. _J Clin Endocrinol Metab_ 71: 15–18. Article  CAS  Google

Scholar  * Igout A, Scippo ML, Frankenne F, Hennen G 1988 Cloning and nucleotide sequence of placental hGH-V cDNA. _Arch Int Physiol Biochem_ 96: 63–67. CAS  Google Scholar  * Frankenne F,

Alsat E, Scippo ML, Igout A, Hennen G, Evain-Brion D 1992 Evidences for the expression of growth hormone receptors in human placenta Biochem Biophys Res Commun 182: 481–483 * Patel N, Alsat

E, Igout A, Baron F, Hennen G, Porquet D, Evain-Brion D 1995 Glucose inhibits human placental GH secretion, _in vitro_. _J Clin Endocrinol Metab_ 80: 1743–1746. CAS  PubMed  Google Scholar 

* Leroy B, Lefort F 1971 A propos du poids et de la taille des nouveaux-nés a la naissance. _Rev Fr Gynecol Obstet_ 66: 391–396. CAS  PubMed  Google Scholar  * Benirschke K, Kaufmann P 1990

Pathology of the Human Placenta, 2nd Ed. Springer-Verlag, New York, 870 Chapter  Google Scholar  * Chowen JA, Steiner RA, Clifton DK 1991 Semiquantitative analysis of cellular somatostatin

mRNA levels by _in situ_ hybridization histochemistry. In: Conn PM (ed) _Methods in Neurosciences_. Academic Press, San Diego, 137–158. Google Scholar  * Jara CS, Salud AT, Bryant-Greenwood

GD, Pirens G, Hennen G, Frankenne F 1989 Immunocytochemical localization of the human growth hormone variant in the human placenta. _J Clin Endocrinol Metab_ 69: 1069–1072. Article  CAS 

Google Scholar  * DeZeghers F, Vanderschueren-Lodeweyckx M, DeZeghers F, Vanderschueren-Lodeweyckx M, Spitz B, Faijerson Y, Blomberg F, Beckers A, Hennen G, Frankenne F 1990 Perinatal growth

hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. _J Clin Endocrinol Metab_ 77: 520–522. Article  Google Scholar  *

Humbel RE 1990 Insulin-like growth factors I and II. _Eur J Biochem_ 190: 445–462. Article  CAS  Google Scholar  * Challier JC, Frankenne F, Bintein T, Poncelet M, Hennen G 1991 Release of

placental growth hormone by perfused human placenta. _Placenta_ 12: 377–378. (abstr) Google Scholar  * Wang C-Y, Daimon M, Shen SJ, Engelmann GL, Ilan J 1988 Insulin-like growth factor-I

messenger ribonucleic acid in the developing human placenta and in term placenta of diabetics. _Mol Endocrinol_ 2: 217–229. Article  CAS  Google Scholar  * Sands J, Dobbing J 1985 Continuing

growth and development of the third-trimester human placenta. _Placenta_ 6: 13–22. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS The authors thank Dr. Francis Frankenne

for the kind gift of the GH-V oligonucleotide. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Cajal Institute, C.S.I.C., 28002 Madrid, Spain J A Chowen, L M García-Segura & J Argente *

Inserm U 427, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, Université René Descartes, Paris V, France D Evain-Brion & E Alsat * Autonomous University, the Hospital of

Niño Jesús, Madrid, Spain J Pozo & J Argente Authors * J A Chowen View author publications You can also search for this author inPubMed Google Scholar * D Evain-Brion View author

publications You can also search for this author inPubMed Google Scholar * J Pozo View author publications You can also search for this author inPubMed Google Scholar * E Alsat View author

publications You can also search for this author inPubMed Google Scholar * L M García-Segura View author publications You can also search for this author inPubMed Google Scholar * J Argente

View author publications You can also search for this author inPubMed Google Scholar ADDITIONAL INFORMATION Supported by grants from the EEC (JUTL 91.0004), Fundación de Endocrinología y

Nutrición, and la Fondation pour la Recherche Médicale. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Chowen, J., Evain-Brion, D., Pozo, J. _et al._

Decreased Expression of Placental Growth Hormone in Intrauterine Growth Retardation. _Pediatr Res_ 39, 736–739 (1996). https://doi.org/10.1203/00006450-199604000-00028 Download citation *

Received: 24 October 1995 * Accepted: 08 December 1995 * Issue Date: 01 April 1996 * DOI: https://doi.org/10.1203/00006450-199604000-00028 SHARE THIS ARTICLE Anyone you share the following

link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature

SharedIt content-sharing initiative